Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 481

Sort by

Sort Order Select

Journal Articles

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Blood (2021) 137 (11): 1527–1537.

https://doi.org/10.1182/blood.2020006923

Published: 2021

Includes: Supplemental data

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Blood (2020) 135 (10): 735–742.

https://doi.org/10.1182/blood.2019003127

Published: 2020

Includes: Supplemental data

Journal Articles

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Fahrettin Covut, MD, Tariq Zuheir Kewan, MD, Apoorva Anandan, MD, Folashade Otegbeye, MBBChir,MPH, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 2196.

https://doi.org/10.1182/blood-2019-125954

Published: 2019

Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 4742.

https://doi.org/10.1182/blood-2019-124191

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Binod Dhakal, MBBS, Raphael Fraser, PhD, Zhubin Gahvari, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Saurabh Chhabra, MD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 783.

https://doi.org/10.1182/blood-2019-126646

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Interim FDG-PET/CT Is an Independent Predictor of Overall Survival and Progression Free Survival in a Real-Life Cohort

Adriana Roque, MD, Dulcelena Neves, MD, Maria Carolina Afonso, MD, Raquel Guilherme, MD, Marília Gomes, MD, Maria Leticia Ribeiro, MD PhD

Blood (2019) 134 (Supplement_1): 1566.

https://doi.org/10.1182/blood-2019-131413

Published: 2019

Journal Articles

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Ehsan Malek, MD, Petra Martin, Paolo F Caimi, MD, Benjamin K. Tomlinson, MD, Michael Caldwell, Gayathri Ravi, MD, Sowjanya Vuyyala, MD, Hannah Schmikla, RN, Robert Fox, Marcos de Lima, MD, Navid Sadri, MD, James Driscoll, MD PhD

Blood (2019) 134 (Supplement_1): 515.

https://doi.org/10.1182/blood-2019-127335

Published: 2019

Journal Articles

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Evangelos Terpos, MD PhD, Ramón García-Sanz, MD PhD, Kazuyuki Shimizu, MD, Wolfgang Willenbacher, MD PhD, Anthony Glennane, MD, Tian Dai, PhD, Walraud Pasteiner, PhD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 606.

https://doi.org/10.1182/blood-2019-127290

Published: 2019

Journal Articles

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Ehsan Tabari, PhD, Alexander F Lovejoy, PhD, Hai Lin, PhD, Christopher R Bolen, PhD, Seng Lor Saelee, BA, Joshua P Lefkowitz, David M. Kurtz, MD PhD, Patrik Vitazka, MD PhD, Jeffrey M. Venstrom, MD PhD, Tina G Nielsen, MD PhD, Joana M Parreira, MD, Daniel M Klass, PhD, Khai T Luong, PhD

Blood (2019) 134 (Supplement_1): 490.

https://doi.org/10.1182/blood-2019-123633

Published: 2019

Journal Articles

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

Blood (2019) 134 (Supplement_1): 3080.

https://doi.org/10.1182/blood-2019-131835

Published: 2019

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Asim Tameez ud din, MD, Muhammad Qudrat Ullah, MD, Muhammad Yasir Anwar, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Zunairah Shah, MBBS, Ahmed Ibrahim, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5579.

https://doi.org/10.1182/blood-2019-123296

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Journal Articles

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Nisha De Silva, MBBS, MRCP, FRCPath, Sandra Robrecht, PhD, Can Zhang, PhD, Paula Cramer, Anna- Maria Fink, MD, Kirsten Fischer, MD, Valentin Goede, MD, Carmen D. Herling, MD PhD, Manuela Hoechstetter, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4293.

https://doi.org/10.1182/blood-2019-126528

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Interim FDG-PET/CT Is an Independent Predictor of Overall Survival and Progression Free Survival in a Real-Life Cohort

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only